Abstract:Multiple sclerosis [MS] is a progressive autoimmune condition that primarily affects young people and is characterized by demyelination and neurodegeneration of the central nervous system [CNS]. This in-depth review explores the complex involvement of oligodendrocytes, the primary myelin- producing cells in the CNS, in the pathophysiology of MS. It discusses the biochemical processes and signalling pathways required for oligodendrocytes to function and remain alive, as well as how they might fail and cause demyelination to occur. We investigate developing therapeutic options that target remyelination, a fundamental component of MS treatment. Remyelination approaches promote the survival and differentiation of oligodendrocyte precursor cells [OPCs], restoring myelin sheaths. This improves nerve fibre function and may prevent MS from worsening. We examine crucial parameters influencing remyelination success, such as OPC density, ageing, and signalling pathway regulation [e.g., Retinoid X receptor, LINGO-1, Notch]. The review also examines existing neuroprotective and antiinflammatory medications being studied to see if they can assist oligodendrocytes in surviving and reducing the severity of MS symptoms. The review focuses on medicines that target the myelin metabolism in oligodendrocytes. Altering oligodendrocyte metabolism has been linked to reversing demyelination and improving MS patient outcomes through various mechanisms. We also explore potential breakthroughs, including innovative antisense technologies, deep brain stimulation, and the impact of gut health and exercise on MS development. The article discusses the possibility of personalized medicine in MS therapy, emphasizing the importance of specific medicines based on individual molecular profiles. The study emphasizes the need for reliable biomarkers and improved imaging tools for monitoring disease progression and therapy response. Finally, this review focuses on the importance of oligodendrocytes in MS and the potential for remyelination therapy. It also underlines the importance of continued research to develop more effective treatment regimens, taking into account the complexities of MS pathology and the different factors that influence disease progression and treatment.

Impaired metabolism of oligodendrocyte progenitor cells and axons in demyelinated lesion and in the aged CNS

Microglia Impede Oligodendrocyte Generation in Aged Brain

Alterations of Oligodendrocyte and Myelin Energy Metabolism in Multiple Sclerosis

Restoring Nuclear Entry of Sirtuin 2 in Oligodendrocyte Progenitor Cells Promotes Remyelination During Ageing

[Mechanisms Underlying Remyelination with Special Focus on Demyelination Models of Multiple Sclerosis].

Oligodendrocyte progenitor programming and reprogramming: Toward myelin regeneration

Targeting Oligodendrocyte Dynamics and Remyelination: Emerging Therapies and Personalized Approaches in Multiple Sclerosis Management

Demyelinating processes in aging and stroke in the central nervous system and the prospect of treatment strategy

Integrating Lipidomics and Transcriptomics Reveals the Crosstalk Between Oxidative Stress and Neuroinflammation in Central Nervous System Demyelination

Targeting Microglia and Macrophages: A Potential Treatment Strategy for Multiple Sclerosis

Integrative Systems and Functional Analyses Reveal a Role of Dopaminergic Signaling in Myelin Pathogenesis.

Senescent-like microglia limit remyelination through the senescence associated secretory phenotype

Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials

Modulation of microglial metabolism facilitates regeneration in demyelination

Mechanisms of Demyelination and Remyelination Strategies for Multiple Sclerosis

Replenishing the Aged Brains: Targeting Oligodendrocytes and Myelination?

Mitochondrial and metabolic dysfunction of peripheral immune cells in multiple sclerosis

Regulation of Oligodendrocyte Functions: Targeting Lipid Metabolism and Extracellular Matrix for Myelin Repair

Long‐term demyelination and aging‐associated changes in mice corpus callosum; evidence for the role of accelerated aging in remyelination failure in a mouse model of multiple sclerosis

Aging, Cellular Senescence, and Progressive Multiple Sclerosis

DOR activation in mature oligodendrocytes regulates α-ketoglutarate metabolism leading to enhanced remyelination in aged mice